ProQR Therapeutics N.V. Ordinary Shares

ProQR Therapeutics announced the nomination of Dr. Lykke Hinsch Gylvin, Chief Medical Officer at Boehringer Ingelheim, to its Board of Directors. Dr. Gylvin brings over 20 years of pharmaceutical leadership experience from roles at Boehringer Ingelheim, Novartis, AstraZeneca, Roche, Novo Nordisk, and Lundbeck. The nomination will be submitted for...

ProQR Therapeutics announced pipeline expansion with multiple clinical programs advancing toward the clinic. The company's lead program AX-0810 is on track to report target engagement data in H1 2026, with biliary atresia selected as the initial Phase 2 indication. Additional programs AX-0811, AX-0422, and AX-2911 are progressing with anticipated...

ProQR Therapeutics reported €92.4 million in cash at year-end 2025 and advanced its lead program AX-0810 into Phase 1 testing for cholestatic diseases, with target engagement data expected in H1 2026. The company selected development candidates AX-2402 for Rett syndrome and AX-2911 for MASH, achieved $4.5 million in Eli Lilly collaboration mile...

ProQR Therapeutics will participate in the 8th Annual Evercore Healthcare Conference, presenting its Axiomer™ RNA editing technology platform that enables targeted single nucleotide changes in RNA to potentially develop new disease treatments.

ProQR Therapeutics received Clinical Trial Application (CTA) authorization from the Central Committee on Research Involving Human Subjects for a Phase 1 study of AX-0810, an investigational RNA editing oligonucleotide targeting NTCP for cholestatic diseases. The company will host a virtual investor event on November 3, 2025 to discuss the clinica...